The professional's guide to product selection
Short-acting selective beta2 agonist.
For acute bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: Initially 100–200 micrograms, up to 800 micrograms daily for persistent symptoms.
For prophylaxis of allergen- or exercise-induced bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: 200 micrograms.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Injection
• Child 1–23 months, by intravenous injection over 5 minutes: 5 mcg/kg as a single dose.
• Child 2–17 years, by intravenous injection over 5 minutes: 15 mcg/kg (maximum 250 mcg) as a single dose.
• Adult, subcutaneous or intramuscular injection: 500 mcg, repeated every four hours if necessary.
• Adult, by slow intravenous injection: (dilute to a concentration of 50 mcg/ml), 250 mcg, repeated if necessary.
Infusion
• Child 1 month–18 years: 1–2 mcg/kg/minute, adjusted according to response and heart rate, up to 5 mcg/kg/minute. Doses above 2 mcg/kg/minute should be given in an intensive care setting.
• Adult, by intravenous infusion: initially 5 mcg/minute, adjusted according to response and heart rate, usually in range 3–20 mcg/minute, or more if necessary.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Short-acting selective beta2 agonist.
Injection
• Child 1–23 months, by intravenous injection over 5 minutes: 5 mcg/kg as a single dose.
• Child 2–17 years, by intravenous injection over 5 minutes: 15 mcg/kg (maximum 250 mcg) as a single dose.
• Adult, subcutaneous or intramuscular injection: 500 mcg, repeated every four hours if necessary.
• Adult, by slow intravenous injection: (dilute to a concentration of 50 mcg/ml), 250 mcg, repeated if necessary.
Infusion
• Child 1 month–18 years: 1–2 mcg/kg/minute, adjusted according to response and heart rate, up to 5 mcg/kg/minute. Doses above 2 mcg/kg/minute should be given in an intensive care setting.
• Adult, by intravenous infusion: initially 5 mcg/minute, adjusted according to response and heart rate, usually in range 3–20 mcg/minute, or more if necessary.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
For prophylaxis of asthma with Seffalair Spiromax® 12.75/100 by inhalation of powder
Child 12–17 years: 1 inhalation twice daily.
Adult: 1 inhalation twice daily.
For prophylaxis of asthma with Seffalair Spiromax® 12.75/202 by inhalation of powder
Child 12–17 years: 1 inhalation twice daily.
Adult: 1 inhalation twice daily.